The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy
Table 3
(a) The detailed clinical characteristics of RRMS patients prior to inclusion in the II-line treatment
Group
FG
NT
Time of I-line treatment (years)
2 ± 2
2 ± 2.5
Type of treatment in I-line:
INF beta-1a (%)
35.9
40
INF beta-1b (%)
46.15
45
OG (%)
17.95
15
EDSS (pkt)
3.5 ± 1
3.5 ± 1
ARR (N)
2.02 ± 0.77
2.31 ± 0.73
Gd + MRI lesions (N)
2 ± 4
3 ± 3
T2 MRI lesions (N)
18.39 ± 5.70
14.56 ± 8.19
(b) The detailed clinical characteristics of RRMS patients after inclusion in the II-line treatment
Group
FG
NT
Time of II-line treatment (years)
2.14 ± 1.39
2.09 ± 1.27
0.841
% of patients without relapses
71.43
87.50
0.143
% of patients without clinical progression
28.57
33.33
0.721
% of patients without radiological progression
93.75
95.83
0.732
T2 MRI lesions (N)
20.25 ± 1.86
18.50 ± 4.90
0.380
RRMS INF: RRMS patients treated with interferon beta; FG: RRMS patients treated with fingolimod; NT: RRMS patients treated with natalizumab; OG: RRMS patients treated with octan glatiramer; EDSS: Expanded Disability Status Scale; ARR: annualized relapse rate; statistical significance for .
